For Q1 FY2026 ended March 31, 2026, Elanco reported revenue of $1.371 billion, up 14.9% year-over-year. Net income was $57 million, down 14.9% from the prior year. Diluted EPS was $0.11, a decrease of 15.4%. The company held $428 million in cash, $3.736 billion in long-term debt, and $6.5 billion in equity.
•Revenue increased 14.9% YoY to $1.371 billion.
•Net income decreased 14.9% YoY to $57 million.
•Diluted EPS fell 15.4% to $0.11.
•Cash and equivalents stood at $428 million; long-term debt was $3.736 billion.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Elanco Animal Health Incorporated, an animal health company, innovates develops, manufactures, and markets products for pets and farm animals globally. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks.
Its portfolio also includes prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus, vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks, and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications
Osteoarthritis for dogs and cats under the Galliprant trademark Farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. Additionally, it offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle
Under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry, as well as other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and Tru Family trademarks
Farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. The company sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Founded in 1954, Elanco Animal Health is headquartered in Indianapolis, Indiana.
What does Elanco Animal Health Incorporated (ELAN) do?
Elanco Animal Health Incorporated is an animal health company that innovates, develops, manufactures, and markets products for pets and farm animals globally. For pets, the company offers parasiticides, vaccines, and therapeutics under well-known brands such as Seresto, K-9 Advantage, Advantix, Advocate, Credelio Family, Interceptor Plus, Drontal family, and Galliprant. These products protect pets from fleas, ticks, internal parasites, and treat conditions like pain, otitis, cardiovascular issues, dermatology indications, and osteoarthritis. For farm animals including cattle, swine, and poultry, Elanco provides medicated feed additives, injectable antibiotics, vaccines, insecticides, and enzymes under brands like Rumensin, Baytril, Experior, Maxiban, and Monteban. The company also offers other pet health products under Atopica, Milbemax, Onsior, and Tru Family trademarks, and farm animal products under AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax trademarks.
Where is Elanco Animal Health (ELAN) listed and in which currency?
Elanco Animal Health Incorporated is listed on the New York Stock Exchange (NYSE) under the ticker symbol ELAN. The company trades in US Dollars (USD), as it is headquartered in the United States. Being listed on the NYSE provides liquidity and exposure to a broad base of global investors, and the use of USD as the trading currency aligns with its primary market and financial reporting.
What sector and industry does Elanco Animal Health (ELAN) belong to?
Elanco Animal Health operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. This classification reflects the company's focus on developing and manufacturing pharmaceutical products for animals, including both prescription and over-the-counter treatments. As a specialty drug manufacturer, Elanco targets specific therapeutic areas in animal health, such as parasiticides, vaccines, and therapeutics for pets and farm animals. The generic aspect indicates that some of its products may be off-patent or non-branded, though the company also markets many branded products.
What are the main product segments for Elanco Animal Health (ELAN)?
Elanco Animal Health's product portfolio is divided into two main segments: pet health and farm animal health. For pets (dogs and cats), the company offers parasiticides (e.g., Seresto, K-9 Advantage, Advantix, Advocate, Credelio Family, Interceptor Plus, Drontal family), vaccines, and therapeutics (e.g., Galliprant for osteoarthritis, Atopica, Milbemax, Onsior, Tru Family). For farm animals, including cattle, swine, and poultry, Elanco provides medicated feed additives (e.g., Rumensin), injectable antibiotics (e.g., Baytril), vaccines (e.g., AviPro), insecticides, and enzymes (e.g., Experior, Maxiban, Monteban, Catosal, Denagard, Hemicell, Pulmotil, Surmax). These products help improve animal health, prevent diseases, and enhance livestock productivity.
Where does Elanco Animal Health (ELAN) operate geographically?
Elanco Animal Health operates globally, serving markets for pets and farm animals worldwide. The company is headquartered in the United States, which is its primary market, but its products are distributed internationally. The description summary indicates that Elanco markets its products globally, covering regions such as North America, Europe, and other parts of the world. The company's portfolio includes brands that are recognized internationally, and its farm animal products address the needs of cattle, swine, and poultry farmers across different geographies. This global presence allows Elanco to cater to diverse animal health needs and regulatory environments.